Our portfolio

We are the largest buyer of biopharmaceutical royalties and the partner of choice for biopharma funding solutions. This gives us access to a rich pipeline of opportunities and has helped us to build an enviable portfolio of market-leading therapies.

vorasidenib

Low-grade glioma

Year of acquisition Status at acquisition
2024Pre-Approval

frexalimab

Multiple sclerosis

Year of acquisition Status at acquisition
2024Pre-Approval

ecopipam

Tourette Syndrome

Year of acquisition Status at acquisition
2024Pre-Approval

TEV-‘749

Schizophrenia

Year of acquisition Status at acquisition
2023Pre-Approval

Evrysdi

Spinal muscular atrophy

Year of acquisition Status at acquisition
2023Approved
2020Pre-Approval

Skytrofa

Growth hormone deficiency

Year of acquisition Status at acquisition
2023Approved

Adstiladrin

Bladder cancer

Year of acquisition Status at acquisition
2023Approved

KarXT

Schizophrenia

Year of acquisition Status at acquisition
2023Pre-Approval

Spinraza

Spinal muscular atrophy

Year of acquisition Status at acquisition
2023Approved

pelacarsen

Cardiovascular disease

Year of acquisition Status at acquisition
2023Pre-Approval

olpasiran

Cardiovascular disease

Year of acquisition Status at acquisition
2022Pre-Approval

MK-8189

Schizophrenia

Year of acquisition Status at acquisition
2022Pre-Approval

Trelegy Ellipta

Chronic obstructive pulmonary disease, asthma

Year of acquisition Status at acquisition
2022Approved

ampreloxetine

Symptomatic neurogenic orthostatic hypotension

Year of acquisition Status at acquisition
2022Pre-Approval

aficamten

Cardiovascular disease

Year of acquisition Status at acquisition
2022Pre-Approval

Orladeyo

Hereditary angioedema

Year of acquisition Status at acquisition
2021Approved
2020Approved

BCX10013

Paroxysmal nocturnal hemoglobinuria

Year of acquisition Status at acquisition
2021Pre-Approval

Tremfya

Plaque psoriasis, active psoriatic arthritis

Year of acquisition Status at acquisition
2021Approved

tulmimetostat

Solid tumors

Year of acquisition Status at acquisition
2021Pre-Approval

trontinemab

Alzheimer’s disease

Year of acquisition Status at acquisition
2021Pre-Approval

pelabresib

Blood cancer

Year of acquisition Status at acquisition
2021Pre-Approval

Oxlumo

Primary hyperoxaluria type 1

Year of acquisition Status at acquisition
2021Approved

Cabometyx/Cometriq

Kidney, liver and thyroid cancer

Year of acquisition Status at acquisition
2021Approved

seltorexant

Major depressive disorder with insomnia symptoms

Year of acquisition Status at acquisition
2021Pre-Approval

Kalydeco

Cystic fibrosis

Year of acquisition Status at acquisition
2020Approved
2014Approved

Orkambi

Cystic fibrosis

Year of acquisition Status at acquisition
2020Approved
2014Approved

Symdeko

Cystic fibrosis

Year of acquisition Status at acquisition
2020Approved
2014Pre-Approval

Trikafta

Cystic fibrosis

Year of acquisition Status at acquisition
2020Approved
2014Pre-Approval

Nurtec ODT

Migraine

Year of acquisition Status at acquisition
2020Approved
2018Pre-Approval

Zavzpret

Migraine

Year of acquisition Status at acquisition
2020Pre-Approval
2018Pre-Approval

IDHIFA

Blood cancer

Year of acquisition Status at acquisition
2020Approved

Prevymis

Cytomegalovirus infection

Year of acquisition Status at acquisition
2020Approved

Entyvio

Ulcerative colitis, Crohn's disease

Year of acquisition Status at acquisition
2020Approved

Tazverik

Epithelioid sarcoma, follicular lymphoma

Year of acquisition Status at acquisition
2019Pre-Approval

Crysvita

X-linked hypophosphatemia

Year of acquisition Status at acquisition
2019Approved

Erleada

Prostate cancer

Year of acquisition Status at acquisition
2023Approved
2019Approved

Emgality

Migraine

Year of acquisition Status at acquisition
2019Approved

Promacta

Chronic immune thrombocytopenia

Year of acquisition Status at acquisition
2019Approved

Trodelvy

Breast cancer

Year of acquisition Status at acquisition
2018Pre-Approval

Airsupra

Asthma

Year of acquisition Status at acquisition
2023Approved
2018Pre-Approval

Tysabri

Multiple sclerosis

Year of acquisition Status at acquisition
2017Approved

Xtandi

Prostate cancer

Year of acquisition Status at acquisition
2016Approved

Bosulif

Blood cancer

Year of acquisition Status at acquisition
2014Pre-Approval

Soliqua

Diabetes

Year of acquisition Status at acquisition
2012Pre-Approval

imbruvica

Blood cancer

Year of acquisition Status at acquisition
2013Pre-Approval

Cimzia

Rheumatoid arthritis

Year of acquisition Status at acquisition
2012Approved

Mircera

Chronic kidney disease

Year of acquisition Status at acquisition
2012Approved

Januvia

Diabetes

Year of acquisition Status at acquisition
2011Approved

Onglyza

Diabetes

Year of acquisition Status at acquisition
2011Approved

Lexiscan

Pharmacological stress agent for myocardial perfusion imaging

Year of acquisition Status at acquisition
2011Approved

Letairis

Pulmonary arterial hypertension

Year of acquisition Status at acquisition
2009Approved

Stay up to date

Subscribe to Royalty Pharma news and alerts

Subscribe